ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "monoclonal antibodies and rheumatoid arthritis (RA)"

  • Abstract Number: 1935 • 2018 ACR/ARHP Annual Meeting

    Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate

    Jiayin Huang1, Tomasz Wojtkowski1, Paul Blahunka1, Ronald Smulders2 and Christopher Lademacher1, 1Astellas Pharma US, Inc., Northbrook, IL, 2Astellas Pharma Europe BV, Leiden, Netherlands

    Background/Purpose: Joint synovium is the main tissue involved in rheumatoid arthritis (RA) lesions. Alpha9 integrin is expressed by synovial tissue lining cells and has been…
  • Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting

    Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Hisanori Umehara3, Toshihiro Nanki4, Nobuyuki Yasuda5, Fumitoshi Tago6, Makoto Kawakubo6, Yasumi Kitahara6, Seiichiro Hojo6, Tetsu Kawano7 and Toshio Imai7, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan, 4Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, 5KAN Research Institute, Inc., Tokyo, Japan, 6Eisai Co., Ltd., Tokyo, Japan, 7KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…
  • Abstract Number: 1588 • 2016 ACR/ARHP Annual Meeting

    Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)

    Sudha Visvanathan1, Meera Ramanujam1, Corinna Schoelch2, Patrick Baum2, Richard Vinisko1, Ralf Thiedmann2, Ulf Müller-Ladner3, Stefan Daniluk4, Rafal Ptaszyński5, Steven Padula6, Jay S. Fine1 and Jürgen Steffgen2, 1Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 3Giessen University, Kerckhoff-Klinik, Bad-Nauheim, Germany, 4ClinicMed Badurski and Partners, Bialystok, Poland, 5Rheumatica, Warsaw, Poland, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

    Background/Purpose: Costimulation through the CD40–CD40L axis is implicated in the pathogenesis of RA including T cell-mediated responses, B cell-driven autoantibodies, adhesion molecule expression, synovial hyperplasia…
  • Abstract Number: 1632 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies

    Mark C. Genovese1, Roy Fleischmann2, Erin Mangan3, Janet van Adelsberg4, Melitza Iglesias-Rodriguez5, Deborah Dukovic6, Chunpeng Fan7 and Tom WJ Huizinga8, 1Stanford University Medical Center, Palo Alto, CA, 2Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Sanofi Genzyme, Cambridge, MA, 6Sanofi Genzyme, Bridgewater, NJ, 7Biostatistics, Sanofi Genzyme, Bridgewater, NJ, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy of sarilumab + MTX was demonstrated in patients with RA and inadequate response to MTX…
  • Abstract Number: 1633 • 2016 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis

    Désirée van der Heijde1, Janet van Adelsberg2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez4, Erin Mangan5, Neil Graham5, Deborah Dukovic3, Alberto Spindler6 and Mark C. Genovese7, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Sanofi Genzyme, Cambridge, MA, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Rheumatology, Universidad Nacional Tucumán, Yerba Buena Tucuman, Argentina, 7Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab + MTX demonstrated significant improvements in RA signs and symptoms, physical function, and inhibition of…
  • Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting

    Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Hisanori Umehara3, Toshihiro Nanki4, Hideto Akama5, Nobuyuki Yasuda5, Fumitoshi Tago5, Makoto Kawakubo5, Seiichiro Hojo5, Tetsu Kawano6 and Toshio Imai6, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, 3Kyoto University Graduate School of Medicine, Kyoto, Japan, 4School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, 5EISAI Co. Ltd., Tokyo, Japan, 6KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
  • Abstract Number: 2874 • 2014 ACR/ARHP Annual Meeting

    Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity

    Khaled Amara1, Lorraine Yeo2, Natalie Sippl1, Philip Titcombe1, Andrew Filer3, Karim Raza3, Dagmar Scheel-Toellner2 and Vivianne Malmström4, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, 2Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, 3Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 4Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose:    Our recent findings identified a subset of pro-inflammatory memory B cells in the RA synovium characterized by the expression of the surface protein…
  • Abstract Number: 2647 • 2013 ACR/ARHP Annual Meeting

    Recombinant Monoclonal Antibodies Derived From Single CD19+ Synovial B Cells Of RA Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones

    Elisa Corsiero1, Michele Bombardieri2, Emanuela Carlotti1, Hedda Wardemann3, William H. Robinson4 and Costantino Pitzalis1, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, 2Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 3Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 4Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Rheumatoid arthritis (RA) is characterised by breach of self-tolerance towards citrullinated proteins. Around 40% of patients display synovial tertiary lymphoid structures (TLS) with functional…
  • Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting

    Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity

    Khaled Amara1, Johanna Steen2, Fiona Murray2, Henner Morbach3, Blanca Fernandez-Rodriguez4, Vijay Balasingh2, Marianne Engström2, Omri Snir2, Lena Israelsson5, Anca Catrina2, Hedda Wardemann6, Davide Corti4, Eric Meffre Sr.3, Lars Klareskog7 and Vivianne Malmström8, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, 2Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 4Institute for Research in Biomedicine, Bellinzona, Switzerland, 5Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 6Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 7Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 8Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…
  • Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

    Mark C. Genovese1, Roy Fleischmann2, Martine Jasson3, Allen R. Radin4, Jennifer Hamilton5 and Tom W.J. Huizinga6, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, 3Clinical Development, Sanofi-Aventis, Paris, France, 4Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology